BIPHETAMINE 20
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIPHETAMINE 20 is an oral extended-release capsule containing an amphetamine combination, approved in 1955 as a small-molecule NDA. The mechanism of action and specific indications are not publicly detailed in available data. This legacy product represents a foundational CNS stimulant therapy.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a consolidating commercial footprint and potential team rightsizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BIPHETAMINE 20 offers limited career growth due to zero linked job openings and LOE-approaching lifecycle stage. Roles on this product are primarily defensive and focused on managing declining market share rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on BIPHETAMINE 20 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.